Scienture Holdings Enhances Healthcare Access for Arbli through Strategic Rebate Agreement

### Scienture's Strategic Advancement in Healthcare Accessibility

Scienture Holdings, Inc. takes a significant step forward in enhancing patient access to its medication, Arbli (losartan potassium) Oral Suspension, 10 mg/mL, by formalizing a commercial Pharmacy Benefit Manager (PBM) led Group Purchasing Organization (GPO) rebate agreement. This strategic agreement aims to secure formulary access for Arbli, enabling the medication to reach a broader patient population. With health plans involved in the agreement covering over 100 million lives, Scienture positions itself to significantly expand the market reach of Arbli, making it more readily available to those who need it.

Through this rebate agreement, Scienture demonstrates its commitment to improving healthcare accessibility, an essential aspect of the pharmaceutical industry. By fostering partnerships with PBMs and GPOs, the company not only enhances its distribution capabilities but also aligns itself with the increasing demand for affordable healthcare solutions. As the healthcare landscape evolves, such collaborations are vital for pharmaceutical companies aiming to provide essential medications to underserved populations. The agreement with the GPO marks a promising development in Scienture's strategy to penetrate the market more effectively and ensure that patients have access to necessary treatments.

The formalization of this rebate agreement is anticipated to play a pivotal role in the distribution and availability of Arbli. By reducing the financial barriers that often prevent patients from obtaining medications, Scienture aims to improve health outcomes for individuals requiring this specific oral suspension formulation. The company’s proactive approach may set a benchmark for how pharmaceutical firms can leverage partnerships to enhance patient access and overall healthcare quality, reinforcing Scienture’s position in the competitive pharmaceutical landscape.

In addition to its focus on Arbli, Scienture Holdings is likely to continue exploring innovative strategies that can further improve healthcare delivery. The establishment of collaborative agreements with various healthcare stakeholders can open pathways for additional products in the future, potentially transforming the company's portfolio. As the industry shifts towards emphasizing patient-centric solutions, Scienture's ongoing efforts could lead to a significant impact on healthcare accessibility.

Overall, the recent advancements signal a robust commitment from Scienture to not only expand its market presence but also to play a crucial role in addressing the healthcare needs of millions. The company's focus on strategic partnerships highlights the importance of collaboration in enhancing medication availability and affordability for patients across the nation.